Clinical Trial Detail

NCT ID NCT02487979
Title Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

osteosarcoma

Therapies

Glembatumumab vedotin

Age Groups: adult child

No variant requirements are available.